Chicago/Paris, April 22, 2025 - Therapixel, the developer of MammoScreen, an Al-based breast cancerscreening software, announces that Mayo Clinic has procured licenses for the use of MammoScreen acrossits radiology departments. The software provides radiologists with Al-generated insights to support theinterpretation of screening mammograms.
Therapixel previously participated in the MedTech Accelerator Program, a Mayo Clinic and Arizona StateUniversity Alliance for Health Care initiative designed to support early-stage health technology companies.Folowing internal evaluations, Mayo Clinic has licensed MammoScreen for use in its clinical workflow.
MammoScreen is designed to assist radiologists by providing decision support in the interpretation ofscreening exams, with the goal of enhancing diagnostic efficiency and accuracy.
"This license agreement represents a meaningful step in making our Al tools accessible to more radiologistsand patients" said Matthieu Leclerc-Chalvet, CEO of Therapixel.
About Therapixel
Therapixel is a leading medical imaging company specializing in Al-driven solutions for radiology. With afocus on breast cancer screening, Therapixel empowers radiologists with cutting-edge technology toimprove diagnostic accuracy, enhance workflow efficiency, and ultimately deliver better patient outcomesCommitted to innovation and quality, Therapixel continually pushes the boundaries of Al to supporthealthcare professionals in detecting cancers earlier and more effectively.